Whalesbook
Promoter Ka Style Change: Selling Se Buyback Ki Taraf
Last two years se market mein thoda correction aur valuations cool down hone ke baad, companies ke promoters ka mood badal gaya hai. Pehle toh yeh log ache rally mein apna maal bech kar nikal jaate thay, lekin abhi valuations kam hone ki wajah se, promoter company ke hi shares buyback kar rahe hain. Iss saal ab tak $4 billion se zyada laga chuke hain yeh log yeh dikhane ke liye ki unko lagta hai stock undervalued hai.
Aur SEBI bhi isko aur easy bana raha hai. Woh open market buyback route ko phir se launch karne ka soch rahe hain, taaki companies apne capital ko aur flexible tareeke se use kar sakein. Yeh route pehle April 1, 2025 se band tha, lekin ab tax changes ke baad isko phir se laane ki baat chal rahi hai.
Kajaria Ceramics: Buyback Price Se 25% Premium, Par Share Neeche
India ki sabse badi tile company, Kajaria Ceramics, ₹297 crore ka buyback laa rahi hai ₹1,380 per share pe. Yeh price aaj ke market price ₹1,062.40 se lagbhag 25% upar hai. Company ke paas kaafi cash hai, jo unke future expenses se zyada hai, toh management ne socha ki buyback se paisa wapas karna tax-efficient rahega. Q4 FY26 mein company ka revenue ₹1,373.35 crore tha aur profit 81.73% jump karke ₹156.56 crore ho gaya. Poore saal FY26 mein sales ₹4,832.50 crore aur EBITDA ₹861.95 crore tha.
Par stock ka RSI indicator mix signal de raha hai (43.3 aur 30.5). Analysts toh isko 'Strong Buy' bol rahe hain aur target ₹1,223 diya hai, jo current price se 10% upar hai. Lekin stock apne 52-week high ₹1,321.90 se kaafi neeche chal raha hai.
Windlas Biotech: CDMO Growth Dikha Raha, Par Stock Chup Chap
Windlas Biotech, jo ek bade CDMO (Contract Development and Manufacturing Organization) mein se ek hai, ₹1,000 per share pe buyback approve kiya hai, jo current market price ₹874.2 se 15% upar hai. Total buyback ₹47 crore ka hai. Yeh CDMO sector mein company ki growth ko support karega, jahan se 73% revenue aata hai. FY26 ke pehle 9 mahine mein revenue 19% badh kar ₹666 crore ho gaya tha aur EBITDA ₹79 crore tha. Poore saal FY25-26 mein revenue ₹777.9 crore aur profit ₹60.99 crore tha. Lekin Q3 FY26 mein net profit 3.7% gira tha year-on-year. Stock pichle saal 8.09% neeche gaya hai. P/E ratio 26.8 hai, jo peers se thoda kam hai. Technical indicators bhi neutral se buy dikha rahe hain.
Jagsonpal Pharmaceuticals: Buyback Price Aur Current Price Mein Bada Gap
Jagsonpal Pharmaceuticals, jo gynaecology aur orthopaedics mein specialized hai, ₹40 crore ka buyback ₹250 per share pe kar rahi hai. Yeh announcement date price se 40% premium aur current price ₹207.05 se 20% upar hai. Company ke paas kaafi free cash flow hai aur ROCE 25.7% tak jaane ka umeed hai. FY26 mein revenue 7% badh kar ₹287 crore aur operating EBITDA ₹61 crore tha. Q4 FY26 mein net profit 33.13% badha tha, par previous quarter se 20% kam tha. Company pe koi debt nahi hai, par stock pichle saal 17.15% gira hai. P/E ratio 32.27 hai, jo ROCE 22.7% aur ROE 17.3% se zyada hai. MarketsMOJO ne toh isko 'Strong Sell' rating diya hai aur RSI bhi 66.2 pe hai.
Toh Yeh Opportunity Hai Ya Value Trap?
Kajaria, Windlas, aur Jagsonpal jaise companies ke buyback price aur current market price mein itna bada gap dekh kar thoda caution dikhana padega. Kajaria ke liye analysts positive hain, par stock RSI aur 52-week low ke aas-paas trade kar raha hai. Windlas mein profit thoda gira hai aur stock neeche gaya hai, toh CDMO growth ka fayda abhi dikh nahi raha. Jagsonpal sabse zyada worrying lag raha hai, 'Strong Sell' rating aur buyback price se kaafi neeche trading, yeh dikhata hai ki market mein kuch problems hain jo management nazarandaaz kar raha hai.
SEBI buyback ko easy bana rahi hai, jisse aise aur buybacks ho sakte hain. Lekin investors ko sirf buyback signal dekh kar invest nahi karna chahiye, fundamentals bhi check karne chahiye, warna value trap mein fas sakte hain.